Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 40/100

Failure Rate

12.5%

1 terminated/withdrawn out of 8 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

25%

2 trials in Phase 3/4

Results Transparency

200%

2 of 1 completed trials have results

Key Signals

1 recruiting2 with results

Enrollment Performance

Analytics

N/A

4(57.1%)

Phase 3

2(28.6%)

Phase 2

1(14.3%)

7Total

N/A(4)

Phase 3(2)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT07465172Not ApplicableNot Yet Recruiting

GDF-15 and Its Relationship With Treatment-related ADverse Events in Breast Cancer

Role: lead

NCT02947685Phase 3Active Not Recruiting

Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer

Role: collaborator

NCT06445738Not ApplicableRecruiting

Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)

Role: lead

NCT02889874Not ApplicableActive Not Recruiting

EXamining PErsonalised Radiation Therapy for Low-risk Early Breast Cancer

Role: lead

NCT02401685Not ApplicableActive Not Recruiting

POSNOC - A Trial Looking at Axillary Treatment in Early Breast Cancer

Role: collaborator

NCT04789096Phase 2Terminated

Tucatinib Together With Pembrolizumab and Trastuzumab

Role: lead

NCT06728150Not Yet Recruiting

Study Investigating the Role of Routine Screening and Molecular Characterisation of Brain Metastasis in the Management of High-risk Metastatic Breast Cancer

Role: collaborator

NCT00659373Phase 3Completed

Brain Function in Premenopausal Women Receiving Tamoxifen With or Without Ovarian Function Suppression for Early-Stage Breast Cancer on Clinical Trial IBCSG 24-02

Role: collaborator

All 8 trials loaded